Addition of docetaxel or abiraterone to androgen deprivation therapy in metastatic castration-naive prostate cancer in South Asian population.

• DOI: 10.1200/jco.2019.37.15_suppl.e16514
• Publication Date: 2019-05-27T16:09:26Z
• Authors: Neha Sonthwal; Shaik Maheboob Hu...; Devavrat Arya; Sandeep Batra; Harit Kumar Chatu...; Alok Gupta
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

e16514 Background: Clinical trials have shown that addition of Docetaxel or Abiraterone to androgen deprivation therapy (ADT) achieves superior survival outcome in metastatic castration naive prostate cancer (mCNPC) predominantly western population. We sought evaluate treatment outcomes adding ADT South Asian Methods: 90 mCNPC patients who received between January 2015 and June 2018 were prospectively followed. Diagnosis was established by TRUS guided biopsy staging done Ga 68 PSMA PET CT scan all patients. Patients unfit for combination alone. diagnosed before 2017 & fit receive chemo-hormonal therapy, ADT+Docetaxel. after offered ADT+Docetaxel ADT+Abiraterone selected based on patient’s choice. Monthly clinical evaluation PSA measurement done. Outcome measures analyzed included decline > 90%, serological complete response (PSA < 0.2 ng/ml) progression CRPC. 76 with atleast 6 months follow-up analysis. Results: alone (N = 37) 31) 22). Median age 72, 64 70 years, median 88, 95 38 ng/ml, Gleason score ≥8 57%, 71% 77% alone, group, respectively. Bone visceral metastasis present 62% 24%, 74% 26%, 68% 23% analysis evaluable is Table. Conclusions: achieve deeper reduced CRPC compared ethnicity. Longer follow up required comment overall also determine which (ADT+Docetaxel ADT+Abiraterone) other, if at all.[Table: see text]